Life Sciences Archive » March, 2022

Life Sciences - March, 2022

327 articles

• $640M Question: 'What Did McKinsey Get' In Big Opioid Deal?
• 3rd Circ. Lets Merck Arbitrate Antitrust Suit Over Vax Prices
• Fed. Circ. Forecast: Cisco To Seek Recusal After $2.7B Loss
• Arbitration-Winning Nutritional Co. Wants $1M In Fees Vacated
• Actavis Must Face Sanctions For Withholding Docs, Man Says
• USTR Cools On Trump-Era China Deal Amid Strategy Pivot
• Becton Dickinson Can't Trim Baxter's Med Pump Patent Suit
• What's Notable In DOJ's 1st Cyber-Fraud Initiative Settlement
• Fla. Hospitals Seek Stay Of State's $65M Endo Opioid Deal
• USPTO Director Review Is A Rare Remedy After Arthrex
• Health Plans Squeezed By Opioid Drug Scheme, 3rd Circ. Told
• Unrepentant Priest Faces 5-Year Injunction In SEC Fraud Case
• 5 Mediation Mistakes That Create Obstacles To Settlement
• Hard-Hit W.Va. Eyes 'Day Of Fate' In Imminent Opioid Trial
• Balwani 'Angry' At Quality Control Advice, Theranos Jury Told
• 6th Circ. Upholds Remand Of Opioid Coverage Dispute
• Fed. Circ. Grills USPTO On Hirshfeld's Power In Arthrex Fight
• Appeals Of J&J Talc Unit's Ch. 11 Heading Directly To 3rd Circ.
• The Problem With GOP Attack On Jackson Immigration Ruling
• Legal Head Of Medical Association Bows Out After 4 Decades
• Biotech Co. Misled Investors About Kidney Drug, Suit Says
• Stroock Adds Patent Litigation Co-Chair From Arnold & Porter
• Faegre Drinker Vet Departs For Philly's Tucker Law Group
• Fla. Inks More Than $878M In Opioid Deals Ahead Of Trial
• Theranos Judge Seals Courtroom For Balwani's Brady Hearing
• Medical Device Group Seeks Win In Copyright Office Suit
• Gilead Can't Force Aetna HIV Suit On Its Terms
• Bill Would Make Contractors Disclose Potential Conflicts
• Biotech Co.'s Creditor Wants In On $3.8M Award Dispute
• Purdue Victims Ask 2nd Circ. To Reverse Ch. 11 Plan Rejection
• FDA Greenlights 2nd COVID Boosters For Some Groups
• German Leader Favors Protecting Patents In WTO Debate
• Emergent Derivative Suit Stayed In Del. Pending Md. Action
• Boston Global Lands $543M In Financing For Mixed-Use Tower
• Fla. High Court Suspends Patent Attorney For 3 Years
• What OIG Rule Change Means For Health Care Innovation
• Cooley Adds Linklaters Antitrust Head To Brussels Office
• Norton Rose Fulbright Adds Commercial Partner In Texas
• Titan Of The Plaintiffs Bar: Simmons Hanly's Jayne Conroy
• $127B HHS 2023 Budget Highlights Vax Access, Mental Health
• Pharmacies Ask 10th Circ. To Stop Cherokee Opioid Suit Move
• ​​​​​​​Illumina Wins Injunction, Loses Triple Damages In BGI IP Case
• Former MiMedx CFO Can't Escape SEC's Fraud Suit
• FDA Seeks $8.4 Billion For 2023 Budget
• Takeaways From Holmes' Unsuccessful Trade Secret Defense
• Attys From Two Firms To Co-Lead CPAP Cleaner MDL
• Claim Of Misuse Of Insys Docs Struck As Bid To 'Taint' Atty
• Ex-NuVasive Rep Must Pay $1.6M For Noncompete Breach
• Law360 Reveals Titans Of The Plaintiffs Bar
• Ethics Principles Call For Justice Thomas Recusal On Election
• Cannabis Data Firm Says Federal Reform A Long Way Off
• Sacklers Say New Ch. 11 Plan Boasts 'Extraordinary' Support
• Holland & Knight Wins Back Litigation Pro From Boutique
• Teva Can't Toss Securities Suit Over Alleged Drug Kickbacks
• 9th Circ. Asked To Rehear Prop 65 Acrylamide Warning Ruling
• Cannabis Bill Roundup: MORE Act To Get Another Floor Vote
• EU, Turkey Agree To Arbitrate Appeals In WTO Clashes
• Merck's Gardasil Vaccine Caused Ga. Teens' Illness, Suits Say
• Fed. Circ. Revives ImmunoGen's Cancer Treatment Patent App
• UK Litigation Roundup: Here's What You Missed In London
• Buchanan Ingersoll Says 'Privileged' Docs' Clawback Too Late
• Kirkland-Led Huntsman Beats Starboard At The Election Box
• Cooley, Davis Polk Rep Lung Disease Biopharma's $69M IPO
• 5 Ways Law Firm Leaders Can Prioritize Strategic Thinking
• Fla. Doctor Convicted Of $112M Drug Treatment Billing Fraud
• Alcon Reaches $20M Lens Price-Fix Deal, Leaving Only J&J
• NJ Pot Regulators OK First Conditional Adult-Use Permits
• IP Forecast: Fed. Circ. To Mull Arthrex's Latest USPTO Fight
• Vitamin C Cos. Ask Justices To Save Price-Fixing Case Again
• Senate Approves Marijuana And CBD Research Bill
• J&J Talc Unit Opposes Claimants' 3rd Circuit Appeal Request
• Texas Deepens Puberty-Blocker Probe Into Endo And AbbVie
• Ranbaxy Confirms 'Global' Deal Resolving Antitrust MDL
• Judge Hands Win To Sandoz In Patent Row With Genentech
• HHS Again Urged To Use March-In Rights To Cut Drug Costs
• DLA Piper Snags 2 Corporate Partners From Faegre Drinker
• Endo Wins Dismissal Of FTC's Suit Over Impax Opioid Deal
• AndroGel Buyers Can't Use FTC Case Against AbbVie, Besins
• Mallinckrodt Creditor Payments Won't Be Held For Appeals
• Cannabis M&A Remains On Fire With $93.3M APIRx Deal
• How Law Schools Can Navigate Toward Equity And Inclusion
• Tearful Theranos Whistleblower Says Boies Threatened Suit
• Opioid MDL Bellwether In SF Gets 'Shocking' Cut To Trial Time
• Moderna Will Seek FDA Approval For Low-Dose Vax For Kids
• Kidney Care Co. Mismanaged Retirement Plan, Suit Says
• Cherokee Opioid Bellwether Suit Is Moved To State Court
• Doctors' Worries Over PE Deals Dominate Merger Comments
• Takeda Asks Fed. Circ. To Undo Trintellix IP Loss
• Shareholders Say Medrobotics Execs Hid Devastating IP Suits
• From Alice To Fintiv: Judge O'Malley Dishes On Patent Law
• US Reinstates Tariff Cuts For More Than 350 Chinese Products
• Where Judge Jackson Stands On Key Civil Procedure Issues
• A Look At Jackson's False Claims Act Jurisprudence
• FDA's Proposed Medical Device Rule Is Promising, But Hasty
• Merck Wins Preemption Ruling In Fosamax Warning MDL
• What DOJ's Shifting Stance On IP Means For SEPs, Mergers
• Attys Seek $4M Fee For BridgeBio Board Pay Suit In Chancery
• Ranbaxy Settles MDL Antitrust Claims For $485M
• SmileDirectClub Can't Nix Claims It Misled On Compliance
• Purdue Gets Another Opioid Suit Freeze Amid Ch. 11 Appeal
• Pharmacy Attys Risking Opioid MDL Sanctions, Judge Warns
• Balwani Blames Holmes As 2nd Theranos Fraud Trial Opens
• Pharma Co. Exits Latest Investor Suit Over Liver Disease Drug
• Trial In Georgia Over Families' Opioid Claims Is Delayed
• 8th Circ. Asked To Follow The 9th In Flavored Vape Ban Case
• Abbott Can't Ax False Ad Attack In Probiotic IP Row
• Zimmer Biomet Bribery Suit Belongs In Mexico, 7th Circ. Says
• Ex-Pfizer Execs Deny Taking Trade Secrets To Their Startup
• Latham-Led Cancer Treatment Co. Wraps Up $175M Financing 
• Conn. Atty Enriched Self With Sham Stock Sales, Jury Hears
• Drug Maker Stole COVID Vax Trade Secrets, $950M Suit Claims
• Justices Skip $420M Secrets Suit, 'Candy Colors' Fight & More
• Sick Juror Gets Cut On Eve Of Ex-Theranos Exec's Fraud Trial
• Becton Dickinson Urges Justices To Reject Baxter's IP Petition
• Boston Hotel Fights Insurer's Win Bid In Virus Coverage Suit
• Fla. Bros. Get Prison For $112M Drug-Treatment Billing Fraud
• Monsanto Seeks High Court Review Of $87M Roundup Verdict
• Amgen Agrees To End Neulasta IP Suit Against Pfizer, Hospira
• 7th Circ. Won't Revive Becton Buyers' Antitrust Suit Again
• Cooley-Led Biopharm Startup Plans For $60M IPO
• DC Group Backs Pharma Cos. In Niaspan Pay-For-Delay Case
• Bioscience Co. Settles Challenge To $70M Private Placement
• Teva Strikes $100M Deal, Ends Rhode Island Opioid Trial
• Catching Up With Delaware's Chancery Court
• How To Avoid Prematurely Publicizing A Case Outcome
• Working With Post-Pandemic Juries On Science-Based Cases
• Bad Bargain? Old Opioid Deal Haunts Fla. AG As Trial Nears
• Mediators Appointed For J&J Talc Unit's Ch. 11 Plan Talks
• Bristol-Myers Sues AstraZeneca Over Cancer Drug Patents
• Fed. Circ. Won't Revive Boston Scientific Implant Patent
• Shkreli Can't Press Pause On $64M Antitrust Judgment
• DC Judge Ends 'Dormant' LabMD Suit Against FTC Attys
• Pfizer Vaccine Delivery Designer Wants Rival's Patents Axed
• Zimmer Can't End Rival's IP Suit Over Knee Replacement Tech
• 5 Steps For Counsel Managing Health Care Data Breaches
• Health Hires: Opentrons Labworks, Conformis
• 9th Circ. Blocks New Prop 65 Acrylamide Warning Label Suits
• IP Forecast: Google To Fight Sonos' Last-Minute Changes
• Mediation Gag Order On Tap For J&J Talc Unit And Claimants
• 9th Circ. Partially Revives SmileDirect's Dental Board Suit
• Human Cell Medical Co. Sues HHS Over Product Reg Dispute
• Jointly, A Pot Ratings App, Raises $5M In Seed Funding
• Latham-Led Triumvira Immunologics Clinches $100M Series A
• Illumina Says Its Ex-Scientists Used Stolen IP To File Patents
• Addressing Patient Requests For Unauthorized Treatment
• How To Wind Down Patents In Russia Over Next 3 Months
• Novartis Loses Bid To Make FDA Block Patent Term Extension
• Rival Says Pfizer And Moderna Vaccines Rely On Its IP
• Roche Unit Nets $775M Deal In AstraZeneca IP Row
• Chancery Sends Stimwave Battle With Founder Toward Trial
• It's Time To Hold DC Judges Accountable For Misconduct
• Goodwin Bulks Up IP Medtech Team In Boston
• Enviro Groups Seek $1.9M Fees In Gene-Modified Salmon Row
• Drug Purchasers Seek Blessing Of Sun And Taro Deals
• COVID IP Waiver Compromise Bashed By All Sides
• Fed. Circ. Won't Review 2 IP Axes Over Written Description
• Daiichi Sankyo Hit With $75K Legal Bill Before Patent Trial
• Husch Blackwell Debuts Psychedelics Practice Team
• Rhode Island AG Opioid Trial Pushed Back
• BCBS Stays In Gilead HIV Suit As More Than An Intermediary
• Health Plans Sue Walgreens Over Prescription Drug Prices
• PTAB Axes Most Of Boston Scientific Rival's Spine Patents
• How To Mitigate Sentencing Liability In Complex Fraud Cases
• J&J Beats Investor's Arbitration Proposal Fight — Again
• NuVasive Nets $1.15M In Spinal Surgery Patent Trial
• Biotech Founders Get 1 Year Each For Stealing Genentech IP
• Balwani Trial Openings Delayed Due To COVID-19 Exposure
• Clifford Chance Adds Hogan Lovells Antitrust Law Expert
• EU, India, South Africa, US Reach Vaccine TRIPS Waiver Deal
• Jury Empaneled In Ex-Theranos Exec Balwani's Fraud Trial
• Long Beach, Others Win OK Of $550M Monsanto PCB Deal
• Akebia Hit With Investor Suit Over Anemia Drug Disclosure
• Del. Judge Trims Purification Patent Suit Against Bio-Rad
• Judge Won't Toss Teva's Migraine Drug IP Suit Against Eli Lilly
• WSJ Again Seeks Release Of Holmes Mental Health Docs
• Deploying Forum Selection Clauses To Bar PTAB Challenges
• Pa. Bio Cos. End Gene Therapy Row In Deal Worth Up To $75M
• Natera Gets Mixed Rulings In Cancer Test Patent Suits
• States Fight Shkreli's Bid To Pause Monetary Penalty
• Full Fed. Circ. Told To Take Crack At Split Narcan Ruling
• Jury Hits Natera With $45M Verdict In CareDx False Ad Suit
• Disney, Walmart Among Cos. Graded F On Pay Gap Disclosure
• 4 Ways To Preserve Confidentiality Of Litigation Funding Docs
• J&J Unit Hit With $20M Verdict In Knee Replacement IP Trial
• How A Drug Co.'s Misreporting Earned A Whistleblower $40M
• McKesson Didn't Rubber-Stamp Opioid Orders, Ex-Exec Says
• Fed. Circ. Was Right To Deny Amgen IP 'Gambit,' Justices Told
• Sensipar Antitrust Claims Trimmed In Amgen, Teva MDL
• Judge OKs $264M Deal Ending Mylan EpiPen Price-Hike Suit
• J&J Investor Fights Arbitration Proposal 'Misstatements'
• CBD Retailer, Manufacturer Denied Sanctions In Patent Row
• Fed. Circ. Affirms PTAB's Ax Of Acne Drug Patent
• Arthrex Says Qualcomm Case Sinks Invalidity Ruling
• Drafting Negative Limitations After Novartis Patent Ruling
• Catching Up With Delaware's Chancery Court
• Navigating Risks In FDA's New Digital Health Tech Guidance
• AMA Hires Ex-IBM Top Health Atty As General Counsel
• Remote Hearings Are Ill-Suited Default For Litigation Realities
• Key Opioid Cases To Watch As Massive Wave Of Trials Looms
• 6th Circ. Orders Opioid MDL Judge To Unfreeze Cases
• Data Co. IQVIA Can't Dispute Trade Secrets Misappropriation
• AOP Orphan Wants Remnants Of €142M Award OK'd In Mass.
• Balwani Wants Altered Theranos Pharma Reports Out Of Trial
• DuPont Can't Shake Fla. Town's Foam Contamination Suit
• Schools End Opioid Claims Against J&J, Distributors
• Cannabis Bill Roundup: Del. Legalization Bill Fails
• 5th Circ. Keeps Medtronic's Win In Defective Device Suit
• 2nd Circ. Backs Dismissal of Bristol-Myers Clinical Trial Suit
• Imerys, Cyprus Extend Mediation On Ch. 11 Talc Settlement
• Air Force Says Ga. Officer Can't Bring Class Claims In Vax Suit
• Astellas Can't Cut Scientists From Stem Cell Patent Apps
• Stays Pending IPR In Del. District Courts Are Here To Stay
• Full Fed. Circ. Asked To Undo Forum Selection Clause Ruling
• ABA's New Anti-Bias Curriculum Rule Is Insufficient
• Don't Miss It: Davis Polk, Paul Weiss Guide Week's Hot Deals
• Moderna's Top Lawyer Saw Pay Near $11.5M Last Year
• Health Hires: Proskauer, Trilogy Health, Pillar Biosciences
• Ill. Emissions Ruling May Hamper Policyholders, Experts Say
• Media Exposure To Holmes Trial Narrows Balwani Jury Pool
• Bausch, Salix's Trimmed IBS Drug IP Suit Moves To W.Va.
• 9th Circ. Won't Revive McKesson Whistleblowers' FCA Suit
• US Senate Confirms María Pagán As WTO Envoy
• Biden Urged To Use Defense Law To Boost Renewable Energy
• 5 Russian, Ukrainian Patent Updates You May Have Missed
• Couple Will Pay $4.6M To End SEC's Insider Trading Claims
• Opioid Victims Get Chance To Confront Sacklers In Court
• 9th Circ. Judges Call COVID Liability Ruling A 'Game Changer'
• Fed. Circ. Gives 7 Patent Appeals Quick Closure
• Drug Patent Critic Hits Back At Claims Research Is Flawed
• Comparing FDA Medical Device Proposal With Global Rules
• Immunotherapy Co. Must Pay NY Broker $2.5M Arb. Award
• Anti-Kickback Safe Harbors May Be Less Safe After Medtronic
• US Judge Finds Conn. Atty Liable For Illegal Stock Sales
• Ex-McDermott Partner Joins O'Melveny Liability Group In NY
• Deals Rumor Mill: Deutsche Telekom, Amazon, Merck
• 2 Firms Rep As Bayer Sells $2.6B Pest Control Biz To PE Firm
• Balwani Jury Prospects Talk Ukraine War, Elizabeth Holmes
• Fed. Circ. Examines Invalidation Of Sanofi Injector Pen Patent
• Tribes Say States Owe Them Part Of Purdue's New $5.5B Deal
• Mass. Rep. Seeks To Destigmatize Medical Pot Use In Vets
• Sheppard Mullin Nabs 5 Life Sci Pros From Loeb & Loeb
• Purdue Gets Approval For New $5.5B Ch. 11 Sackler Deal
• Philips Faces Refund Suit Over Recalled CPAP Devices
• CDC Told To Keep Story Straight In HIV Patent Fight
• Nothing 'Innocuous' In Drugmakers' Dismissal Bid, Court Told
• Alvotech, AbbVie Deal Allows For Humira Biosimilar In 2023
• Fake Vax Seller Nabbed In Sting Dodges Prison
• 5 Advertising Enforcement Trends To Watch
• Lando & Anastasi Life Sciences Leads Join K&L Gates
• Remote Hearings Should Be The Default In Civil Litigation
• Ill. Company Shut Down Over Tainted Supplements
• Wash. AG's Opioid Trial Survives 'Very Significant' Defenses
• UnitedHealth's HIV Drug Suit Against Teva, Gilead Trimmed
• Jones Day Can Stay As J&J Talc Spinoff's Ch. 11 Counsel
• Possible Holmes Testimony Hangs Over Sunny Balwani's Trial
• Hospital System Faces ADA Suit From Medical Marijuana User
• Judge Reluctant To Send J&J Talc Unit's Ch. 11 To 3rd Circ.
• 5th Circ. Questions Basis For Fed. Worker Vax Mandate Freeze
• Attorneys Today Need To Depose Like There's No Tomorrow
• Pharma Co. Says NJ Law Firm Is Misusing Trade Secrets
• States Seek $2.2M In Atty Fees For Joining In Shkreli Case
• NY, NJ Towns Fight $277M 'Hush Money' In Purdue Deal
• Mallinckrodt Inks $260M Deal Ending DOJ Medicaid Claims
• California Pot Regulator Revamps Proposed Cannabis Rules
• Teva Stalled Generics For Blockbuster MS Drug, Buyers Say
• Catching Up With Delaware's Chancery Court
• SPAC CEO Awarded Some Defense Fees For Suits, SEC Probe
• CVS, Walgreens, Walmart Can't Escape Opioid Verdict
• 11th Circ. Says Probation Not Enough For Tricare Fraudster
• Clovis Agrees To Reforms, $2.3M Atty Fee In Drug Trial Suit
• Theranos Judge Trims Jury Pool Over Race Bias, Abuse Views
• Parsing Recent DOJ Statements On Monopolistic Conduct
• Globus' Ex-Sales Rep Says Work Contracts Are Unenforceable
• FCA Trends To Watch For Health, Life Sciences Cos.
• OvaScience, VC Fund Settle Investor Class Action For $15M
• Fed. Circ. Doubts PTAB Wrongly Axed J&J Unit's Surgical IP
• Lab Maker Settles Trade Secrets Suit Against Ex-Executive
• Goodwin Adds Former DOJ Deputy Chief In DC
• Judge Gives First Nod To $4.75M CaptureRx Data Breach Deal
• Mo. Roundup Buyers Say $45M Deal Smells Of Collusion
• Pathway Genomics Investor Says Board Ignored Assets Raid
• 5th Circ. Won't Let States Amend Health Care Vax Challenge
• Valisure Wants Fees For Quashed Subpoena In Zantac MDL
• 7th Circ. Says Suit Alleging Faulty Blood Clot Filter Is Untimely
• Celgene Can't Delay Cancer Drug Antitrust Case, Court Told
• Health Hires: Amylyx, Veracyte
• Athenahealth Whistleblower Wins Fees In $18M Kickback Case
• A Look At This Year's Busy Federal Health Policy Landscape
• Colorado Pharma Co. Investor Sues Over Stock Split, Grant
• Abbott Units Beat Consultant's Training Copyright Suit
• UK Litigation Roundup: Here's What You Missed In London
• Plaintiffs' Bar Irate That J&J's 'Stooge' Ch. 11 Moving Ahead
• Gilead, Teva Look To Trim United Health's HIV Generics Suit
• AmeriHealth Sheds FCA Suit Alleging It Flouted NJ Copay Law
• As EU Unified Patent Court Nears, Companies Mull Opting Out
• IP Forecast: Tech Giants' Voice Tech Row Heads To Fed. Circ.
• AngioDynamics Loses Bid To Pause Patent Row With Bard
• OptumRx Fights To Arbitrate Reimbursement Suit At 3rd Circ.
• Purdue Reaches Final Terms On New $5.5B Ch. 11 Settlement
• ​​​​​​​Regeneron Can't Ditch COVID-19 Tech Patent Suit
• Illumina Looks To Triple $8M Win For BGI DNA IP Infringement
• Women Make Up Just 12% Of Attys In PTAB Cases
• Express Scripts Can't Avoid MTA Prescription Fraud Claims
• Valero Hit With Suit Over Bay Area Petroleum Coke Pollution
• Industry Insights To Navigate AI Chemical Invention Patents
• Philip Morris Gets Redo On $7M Atty Fee In Engle Suit
• Enforcement Risks For COVID Labs To Identify And Avoid
• Full Fed. Circ. Won't Review Mylan's Win In Symbicort IP Fight
• McCarter & English Accused Of Malpractice Over Biotech IP
• Purdue Mediator Extends Talks To Work On Deal Terms
• 3 Product Liability Highlights From The State Of The Union
• High Court Poised To Make DOJ's Job Harder In Opioid Cases
• The Jackson Ruling That Reverberates In Drug Pricing Debate
• Boston Marriott Says Insured Virus Losses Extended Full Year
• 7th Circ. Says Atty's Mistakes Kept Clients Out Of MDL
• Novartis Patent Suit Over Generic MS Drug Won't Be Trimmed
• Acthar Claimants Seek End To Mallinckrodt Litigation Pause
• IPO Market Appears Stalled For The Near Future
• Feds Expect A Trial For Ex-Theranos Exec As Long As Holmes'
• 3 Firms Rep $200M Life Sciences, Sustainable Tech SPAC IPO
• FDA Says Baby's Death May Be Linked To Abbott Formula
• Fla. Appeals Court Likely To Zero Out $148M Punitive Award
• Chancery Asks If It's Right Venue For Biotech Stock Drop Suit
• How Attorneys Can Ethically Terminate A Client Relationship
• GW Pharmaceuticals Beats CBD Patent Infringement Suit
• Supplement Co.'s False Labeling Settlement Gets First OK
• Broad Institute, MIT Win Patent Battle Over CRISPR